Medpace climbs 3% as traders position for Q1 earnings and 2026 outlook
Medpace shares rose about 3.4% Tuesday as investors refocused on 2026 growth after the company’s February outlook called for $2.755–$2.855B of revenue and $16.68–$17.50 GAAP EPS. The stock is also heading into its next earnings catalyst, with Wall Street widely flagging an April 22, 2026 report date.
1. What’s moving the stock today
Medpace Holdings (MEDP) is higher Tuesday as the market leans back into the company’s 2026 growth profile and traders position ahead of the next earnings event. The latest company outlook, issued with full-year 2025 results, forecast 2026 revenue of $2.755 billion to $2.855 billion and GAAP diluted EPS of $16.68 to $17.50, framing expectations for continued growth this year. (investor.medpace.com)
2. The next near-term catalyst: Q1 earnings date
Attention is shifting to Medpace’s upcoming first-quarter 2026 earnings, which multiple market calendars flag for Wednesday, April 22, 2026. With the stock already up meaningfully from the post-February selloff lows, investors are using the approaching report as the next checkpoint on bookings, backlog conversion, and margin trajectory. (benzinga.com)
3. Sentiment backdrop: upgrades and positioning
Sell-side positioning has been mixed, but a key positive overhang remains the February 13, 2026 upgrade to Buy with a $560 price target that highlighted improving biotech funding conditions as a forward driver for CRO demand. Separately, reported short interest increased to about 1.40 million shares in the mid-March reporting period, which can amplify upside on strong tape days if incremental buyers force covering. (m.ng.investing.com)
4. What investors will watch next
The next earnings release is expected to sharpen the debate around whether Medpace can sustain bookings momentum and translate backlog into revenue without further margin compression. Investors will be focused on net new business awards/book-to-bill, updated 2026 guidance assumptions, and any commentary that signals acceleration or softness in demand heading into the second half of 2026. (investor.medpace.com)